Fortis Healthcare Q1 FY27: Revenue up 17.5% to ₹2,545 Cr; Hospital Revenue grows 19%
Fortis Healthcare reported Q1 FY27 consolidated revenues of ₹2,545 Cr, up 17.5% YoY. Hospital revenue rose 19% to ₹2,187 Cr. The company entered an O&M agreement for a 300-bed hospital in Cuttack, Odisha, and plans to add ~1,800 beds in 4-5 years.
The announcement details strong financial performance and significant strategic growth initiatives, including new hospital agreements and capacity expansion, which are expected to positively impact the company's future.
The company reported significant year-on-year revenue growth in both consolidated and hospital businesses, along with strategic expansion plans and entry into new geographies.
Fortis Healthcare Limited announced its unaudited consolidated financial results for the quarter ended June 30, 2026. The company reported consolidated revenues of ₹2,545 crore, an increase of 17.5% year-on-year, with an Operating EBITDA margin of 22.3% (excluding ESOP expenses). The hospital business revenue stood at ₹2,187 crore, up 19.0% year-on-year, with an Operating EBITDA margin of 21.5% (excluding ESOP expenses). The diagnostics business revenue was ₹407 crore, a 10.2% increase year-on-year, with an Operating EBITDA margin of 23.9% (excluding ESOP expenses).
The company's net debt as of June 30, 2026, was ₹2,233 crore. The hospital business saw revenue growth driven by a moderate increase in Average Revenue Per Operating Bed (ARPOB) and a 16.7% rise in occupied beds compared to Q1 FY26. Recent acquisitions in Punjab, Bengaluru, and a leased facility in Delhi NCR contributed to this performance. Excluding these, like-for-like Operating EBITDA margins remained steady at 22%.
Fortis Healthcare has entered into an Operations and Management agreement for a 300-bedded greenfield multi-specialty hospital in Cuttack, marking its entry into Odisha. The company is also pursuing inorganic growth in geographies like Bengaluru and consolidating its shareholding in group businesses. Additionally, brownfield expansion plans include adding approximately 1,800 beds over the next 4-5 years. The company expects consolidated revenue growth in line with market growth and Operating EBITDA margins to gradually improve to the mid-twenties in the next few years.
The diagnostics business, operating as Agilus, added new customer touch points, reaching 4,493 as of June 30, 2026. Agilus conducted approximately 10.46 million tests in Q1 FY27, a slight increase from 10.13 million in Q1 FY26. Preventive and specialized portfolio revenues grew by 27% and 13% respectively.
Dr. Ashutosh Raghuvanshi, MD and CEO, stated that the company made a positive start to the financial year with steady Q1 performance across both businesses. He highlighted the entry into Odisha with the Cuttack hospital O&M agreement and the positive ramp-up of recent acquisitions. He also mentioned investments in robotic systems and the steady revenue growth and improved EBITDA margins in the diagnostics business. The company remains focused on sustained growth through expansion plans, strategic initiatives, and operational excellence.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.